Are We Getting The Medicines We Need? Speakers Ask At European Health Forum Gastein
Executive Summary
Speakers at the recent European Health Forum Gastein conference in Austria claimed that many new drugs don’t really bring a meaningful clinical benefit, and that new ways are needed to assess the value of innovation.
You may also be interested in...
What EU Governments Need To Do About Access To Affordable Medicines
In a wide-ranging discussion at the recent European Health Forum Gastein, policy makers explored big-picture challenges and ideas of what governments should do to ensure access to increasingly expensive medicines as pressures grow on national health care systems.
Novartis Beats CAR-T Competitors To The Pricing Punch With Kymriah Approval
Novartis got a leg up on its competition Aug. 30 with an earlier-than-expected approval for Kymriah in pediatric ALL, ending the CAR-T pricing mystery with its $475,000 price tag, which the company is positioning as a relative bargain.
UK Avoids 'Cliff Edge' By Extending EU Drug Approval Reliance Procedure
The UK drugs regulator says it needs to make sure that companies do not “deprioritize” GB approval applications while a new “international reliance framework” is being developed.